p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos

Lung Cancer

Volumn 67, Issue 1, 2010, Pages 23-30

  Andujar, Pascal ^a,b,c   Wang, Jinhui ^d   Descatha, Alexis ^d,e,f   Galateau Sallé, Françoise ^d,g   Abd Alsamad, Issam ^a   Billon Galland, Marie Annick ^h   Blons, Hélène ^d,i   Clin, Bénédicte ^d,g   Danel, Claire ^i,j   Housset, Bruno ^a,b,c   Laurent Puig, Pierre ^d,i   Le Pimpec Barthes, Françoise ^j,k   Letourneux, Marc ^d,g   Monnet, Isabelle ^a   Régnard, Jean François ^l   Renier, Annie ^i,k   Zucman Rossi, Jessica ^i,k   Pairon, Jean Claude ^a,b,c   Jaurand, Marie Claude ^i,k  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b INSERM U955   (France)

^c FACULTÉ DE MÉDECINE   (France)

^d INSERM   (France)

^e RAYMOND POINCARÉ HOSPITAL   (France)

^f LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^g CAEN UNIVERSITY HOSPITAL   (France)

^h Lab d'Etud des Particules Inhalees   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^k FONDATION JEAN DAUSSET CEPH   (France)

^l CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

more..

Author keywords

Asbestos; Deletion; Hypermethylation; INK4A; Lung cancer; Occupation; P16 CDKN2A; Tobacco smoking

Indexed keywords

ASBESTOS; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TOBACCO SMOKE; TUMOR SUPPRESSOR PROTEIN; CARCINOGEN;

ADULT; ARTICLE; CANCER PATIENT; CIGARETTE SMOKING; CONTROLLED STUDY; CPG ISLAND; EPIDEMIOLOGICAL DATA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE INACTIVATION; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; INCIDENCE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; QUESTIONNAIRE; RISK FACTOR; SMOKING HABIT; SOMATIC MUTATION; AGED; CHEMICALLY INDUCED DISORDER; DNA METHYLATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; SMOKING;

AGED; ASBESTOS; CARCINOGENS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; GENE DELETION; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PROMOTER REGIONS, GENETIC; SMOKING;

EID: 71849104873     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.03.018     Document Type: Article

References (48)

1. Herbst R.S., Heymach J.V., and Lippman S.M. Lung cancer. N Engl J Med 359 (2008) 1367-1380
2. Boffetta P. Human cancer from environmental pollutants: the epidemiological evidence. Mutat Res 608 (2006) 157-162
3. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91 (1999) 1194-1210
4. Axelson O. Alternative for estimating the burden of lung cancer from occupational exposures-some calculations based on data from Swedish men. Scand J Work Environ Health 28 (2002) 58-63
5. Nurminen M., and Karjalainen A. Epidemiologic estimate of the proportion of fatalities related to occupational factors in Finland. Scand J Work Environ Health 27 (2001) 161-213
6. Selikoff I.J., and Hammond E.C. Asbestos and smoking. JAMA 242 (1979) 458-459
7. Le Calvez F., Mukeria A., Hunt J.D., Kelm O., Hung R.J., Taniere P., et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 65 (2005) 5076-5083
8. Mounawar M., Mukeria A., Le Calvez F., Hung R.J., Renard H., Cortot A., et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 67 (2007) 5667-5672
9. Subramanian J., and Govindan R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol 9 (2008) 676-682
10. Gazzeri S., Gouyer V., Vour'ch C., Brambilla C., and Brambilla E. Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene 16 (1998) 497-504
11. Hommura F., Dosaka-Akita H., Kinoshita I., Mishina T., Hiroumi H., Ogura S., et al. Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers. Br J Cancer 81 (1999) 696-701
12. Geradts J., Fong K.M., Zimmerman P.V., Maynard R., and Minna J.D. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 5 (1999) 791-800
13. Lamy A., Sesboue R., Bourguignon J., Dautreaux B., Metayer J., Frebourg T., et al. Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: a prospective study in high-risk patients without invasive cancer. Int J Cancer 100 (2002) 189-193
14. Liu Y., An Q., Li L., Zhang D., Huang J., Feng X., et al. Hypermethylation of p16INK4a in Chinese lung cancer patients: biological and clinical implications. Carcinogenesis 24 (2003) 1897-1901
15. Esteller M., Corn P.G., Baylin S.B., and Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res 61 (2001) 3225-3229
16. Kim D.H., Nelson H.H., Wiencke J.K., Zheng S., Christiani D.C., Wain J.C., et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 61 (2001) 3419-3424
17. Tsou J.A., Hagen J.A., Carpenter C.L., and Laird-Offringa I.A. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 21 (2002) 5450-5461
18. Jarmalaite S., Kannio A., Anttila S., Lazutka J.R., and Husgafvel-Pursiainen K. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. Int J Cancer 106 (2003) 913-918
19. Gu J., Berman D., Lu C., Wistuba I.I., Roth J.A., Frazier M., et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 12 (2006) 7329-7338
20. Nakata S., Sugio K., Uramoto H., Oyama T., Hanagiri T., Morita M., et al. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer 106 (2006) 2190-2199
21. Ruas M., and Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378 (1998) F115-177
22. Yanagawa N., Tamura G., Oizumi H., Takahashi N., Shimazaki Y., and Motoyama T. Frequent epigenetic silencing of the p16 gene in non-small cell lung cancers of tobacco smokers. Jpn J Cancer Res 93 (2002) 1107-1113
23. Iwakawa R., Kohno T., Anami Y., Noguchi M., Suzuki K., Matsuno Y., et al. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma. Clin Cancer Res 14 (2008) 3746-3753
24. Sanchez-Cespedes M., Decker P.A., Doffek K.M., Esteller M., Westra W.H., Alawi E.A., et al. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res 61 (2001) 2092-2096
25. Kraunz K.S., Nelson H.H., Lemos M., Godleski J.J., Wiencke J.K., and Kelsey K.T. Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer. Int J Cancer 118 (2006) 1364-1369
26. Dammann R., Strunnikova M., Schagdarsurengin U., Rastetter M., Papritz M., Hattenhorst U.E., et al. CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer 41 (2005) 1223-1236
27. Lee W.C., and Testa J.R. Somatic genetic alterations in human malignant mesothelioma (review). Int J Oncol 14 (1999) 181-188
28. Hirao T., Bueno R., Chen C.J., Gordon G.J., Heilig E., and Kelsey K.T. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 23 (2002) 1127-1130
29. Ladanyi M. Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer 49 Suppl. 1 (2005) S95-98
30. Pairon J.C., Orlowski E., Iwatsubo Y., Billon-Galland M.A., Dufour G., Chamming's S., et al. Pleural mesothelioma and exposure to asbestos: evaluation from work histories and analysis of asbestos bodies in bronchoalveolar lavage fluid or lung tissue in 131 patients. Occup Environ Med 51 (1994) 244-249
31. De Vuyst P., Karjalainen A., Dumortier P., Pairon J.C., Monso E., Brochard P., et al. Guidelines for mineral fibre analyses in biological samples: report of the ERS Working Group. European Respiratory Society. Eur Respir J 11 (1998) 1416-1426
32. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 (1996) 9821-9826
33. Blons H., Pallier K., Le Corre D., Danel C., Tremblay-Gravel M., Houdayer C., et al. Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. BMC Med Genomics 1 (2008) 25
34. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
35. Kohno T., and Yokota J. How many tumor suppressor genes are involved in human lung carcinogenesis?. Carcinogenesis 20 (1999) 1403-1410
36. Kashiwabara K., Oyama T., Sano T., Fukuda T., and Nakajima T. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. Int J Cancer 79 (1998) 215-220
37. Soria J.C., Rodriguez M., Liu D.D., Lee J.J., Hong W.K., and Mao L. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res 62 (2002) 351-355
38. Belinsky S.A., Palmisano W.A., Gilliland F.D., Crooks L.A., Divine K.K., Winters S.A., et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62 (2002) 2370-2377
39. Toyooka S., Suzuki M., Tsuda T., Toyooka K.O., Maruyama R., Tsukuda K., et al. Dose effect of smoking on aberrant methylation in non-small cell lung cancers. Int J Cancer 110 (2004) 462-464
40. Illei P.B., Rusch V.W., Zakowski M.F., and Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 9 (2003) 2108-2113
41. Musti M., Kettunen E., Dragonieri S., Lindholm P., Cavone D., Serio G., et al. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet 170 (2006) 9-15
42. Yegles M., Janson X., Dong H.Y., Renier A., and Jaurand M.C. Role of fibre characteristics on cytotoxicity and induction of anaphase/telophase aberrations in rat pleural mesothelial cells in vitro: correlations with in vivo animal findings. Carcinogenesis 16 (1995) 2751-2758
43. Murthy S.S., and Testa J.R. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 180 (1999) 150-157
44. Dusinska M., Collins A., Kazimirova A., Barancokova M., Harrington V., Volkovova K., et al. Genotoxic effects of asbestos in humans. Mutat Res 553 (2004) 91-102
45. Lecomte C., Andujar P., Renier A., Kheuang L., Abramowski V., Mellottee L., et al. Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Cell Cycle 4 (2005) 1862-1869
46. Altomare D.A., Vaslet C.A., Skele K.L., De Rienzo A., Devarajan K., Jhanwar S.C., et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 65 (2005) 8090-8095
47. Soufir N., Avril M.F., Chompret A., Demenais F., Bombled J., Spatz A., et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 7 (1998) 209-216
48. Soufir N., Lacapere J.J., Bertrand G., Matichard E., Meziani R., Mirebeau D., et al. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma. Br J Cancer 90 (2004) 503-509